HK1126623A1 - 條件無限增殖化長期幹細胞和製備和使用所述細胞的方法 - Google Patents
條件無限增殖化長期幹細胞和製備和使用所述細胞的方法Info
- Publication number
- HK1126623A1 HK1126623A1 HK09105588.8A HK09105588A HK1126623A1 HK 1126623 A1 HK1126623 A1 HK 1126623A1 HK 09105588 A HK09105588 A HK 09105588A HK 1126623 A1 HK1126623 A1 HK 1126623A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cells
- methods
- stem cells
- making
- conditionally immortalized
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 210000004027 cell Anatomy 0.000 title abstract 5
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 230000007774 longterm Effects 0.000 title 1
- 238000010172 mouse model Methods 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 210000004504 adult stem cell Anatomy 0.000 abstract 1
- 230000011712 cell development Effects 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001671 embryonic stem cell Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72813105P | 2005-10-18 | 2005-10-18 | |
US76599306P | 2006-02-06 | 2006-02-06 | |
PCT/US2006/040379 WO2007047583A2 (en) | 2005-10-18 | 2006-10-18 | Conditionally immortalized long-term stem cells and methods of making and using such cells |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1126623A1 true HK1126623A1 (zh) | 2009-09-11 |
Family
ID=37963171
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09105588.8A HK1126623A1 (zh) | 2005-10-18 | 2009-06-22 | 條件無限增殖化長期幹細胞和製備和使用所述細胞的方法 |
HK16110996.5A HK1222890A1 (zh) | 2005-10-18 | 2009-06-22 | 條件無限增殖化長期幹細胞和製備和使用所述細胞的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16110996.5A HK1222890A1 (zh) | 2005-10-18 | 2009-06-22 | 條件無限增殖化長期幹細胞和製備和使用所述細胞的方法 |
Country Status (13)
Country | Link |
---|---|
US (7) | US8883507B2 (zh) |
EP (1) | EP1942739B1 (zh) |
JP (8) | JP2009511081A (zh) |
KR (2) | KR101441693B1 (zh) |
CN (2) | CN105483088B (zh) |
AT (1) | ATE491022T1 (zh) |
AU (1) | AU2006304392B2 (zh) |
CA (2) | CA3065947C (zh) |
DE (1) | DE602006018768D1 (zh) |
HK (2) | HK1126623A1 (zh) |
IL (7) | IL286053B2 (zh) |
IN (1) | IN2014DN06624A (zh) |
WO (1) | WO2007047583A2 (zh) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL286053B2 (en) | 2005-10-18 | 2023-03-01 | Nat Jewish Health | A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin |
PT2772535T (pt) | 2006-05-31 | 2022-07-04 | Childrens Medical Center | Células estaminais mesenquimais abcb5 positivas como imunomoduladores |
GB0619500D0 (en) * | 2006-10-03 | 2006-11-08 | Univ Keele | Treatment of fibrosis |
EP2134852A4 (en) * | 2007-03-13 | 2010-04-28 | Nat Jewish Health | METHODS OF GENERATING ANTIBODIES |
AU2009246876B2 (en) | 2008-05-16 | 2015-04-02 | Htyr Acquisition Llc | Antibodies and processes for preparing the same |
US9169462B2 (en) * | 2008-07-21 | 2015-10-27 | Taiga Biotechnologies, Inc. | Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells |
EP3916010A1 (en) * | 2008-08-28 | 2021-12-01 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same and methods of identifying agents that modulate myc |
CA2743464A1 (en) | 2008-11-14 | 2010-05-20 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
DK2448967T3 (en) * | 2009-06-29 | 2015-07-20 | Ilya B Leskov | NON-HUMAN MAMMALS MODEL OF CANCER human hematopoietic |
BR112012005710B1 (pt) * | 2009-09-15 | 2020-06-09 | Univ Tokyo | método para produzir células megacariotícas maduras, método para produzir um produto de plaqueta, método para produzir um produto sanguíneo, população celular, composição celular congelada e kit |
AU2014240253B2 (en) * | 2009-09-15 | 2017-08-03 | The University Of Tokyo | Novel Method for Producing Differentiated Cells |
EP2498796B1 (en) | 2009-11-09 | 2017-12-27 | AAL Scientifics, Inc. | Treatment of heart disease |
CN103025865A (zh) * | 2010-05-06 | 2013-04-03 | 干细胞医药有限公司 | 用于个性化医疗的干细胞库 |
US10034900B2 (en) | 2010-09-30 | 2018-07-31 | National University Corporation Kumamoto University | Method of producing myeloid blood cells |
US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
US20130171115A1 (en) * | 2011-12-30 | 2013-07-04 | Gang Li | Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
CN114645015A (zh) * | 2012-07-20 | 2022-06-21 | 泰加生物工艺学公司 | 造血区室的增强的重建和自动重建 |
ES2860573T3 (es) | 2013-02-19 | 2021-10-05 | Childrens Medical Center | Células madre ABCB5(+) para el tratamiento de enfermedades oculares |
US9365825B2 (en) * | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
MX2015015536A (es) | 2013-05-10 | 2016-08-08 | Children's Medical Center Corp | Cicatrización de heridas e ingenieria de tejido. |
KR101638403B1 (ko) * | 2013-07-17 | 2016-07-11 | 아주대학교산학협력단 | RGMc를 유효성분으로 포함하는 줄기세포 유도용 배지 조성물 및 이를 이용한 줄기세포의 유도방법 |
WO2015020993A2 (en) * | 2013-08-05 | 2015-02-12 | The Trustees Of The University Of Pennsylvania | RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA |
CN103509101B (zh) * | 2013-08-12 | 2016-11-02 | 中国科学院广州生物医药与健康研究院 | 一种扩增脐带血造血干细胞的细胞因子及其培养基 |
WO2016149672A1 (en) | 2015-03-18 | 2016-09-22 | The Regents Of The University Of California | Methods of preventing and reversing stem cell aging |
CN106148266A (zh) * | 2015-04-20 | 2016-11-23 | 烟台赛泽生物技术有限公司 | 一种免疫细胞用培养基及该培养基的添加剂 |
CN104928247B (zh) * | 2015-07-02 | 2018-03-23 | 广州赛莱拉干细胞科技股份有限公司 | 一种神经干细胞培养基及神经干细胞贴壁培养方法 |
JP2018520688A (ja) | 2015-07-21 | 2018-08-02 | ザ チルドレンズ メディカル センター コーポレーション | Pd−l1発現造血幹細胞およびその使用 |
AU2016318773B2 (en) | 2015-09-09 | 2024-08-01 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Genetic engineering of macrophages for immunotherapy |
US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
CN105695511A (zh) * | 2016-04-13 | 2016-06-22 | 中国人民解放军第三军医大学 | 一种永生化毛囊干细胞系及其制备方法 |
CN105713880A (zh) * | 2016-04-20 | 2016-06-29 | 广东艾时代生物科技有限责任公司 | 一种造血干细胞体外扩增培养的无血清培养基及其应用 |
CN106279403B (zh) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | 一种检测天然肺癌相关抗体的组合物、试剂盒和方法 |
CN113786476A (zh) | 2016-12-02 | 2021-12-14 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
CN106754728B (zh) * | 2016-12-30 | 2020-05-15 | 中国人民解放军总医院 | 后肾间充质细胞系及其制备方法与应用 |
FR3068366B1 (fr) * | 2017-06-30 | 2023-11-24 | Francais Du Sang Ets | Procede de production de progeniteurs erythroides |
SG11202000724XA (en) * | 2017-08-03 | 2020-02-27 | Taiga Biotechnologies Inc | Methods and compositions for the treatment of cancer |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
US12023357B2 (en) | 2017-10-13 | 2024-07-02 | Hackensack University Medical Center | Rejuvenated aged hematopoietic stem cells and methods of use |
CN107937342B (zh) * | 2017-11-06 | 2021-07-06 | 中国人民解放军第四军医大学 | 一种通过内皮细胞来源的外泌体扩增神经干细胞的方法 |
CN108070567A (zh) * | 2018-01-19 | 2018-05-25 | 皓昇莱生物制药有限公司 | 一种永生化的尿液来源细胞株及其构建方法 |
US20210371828A1 (en) * | 2018-10-12 | 2021-12-02 | Reneuron Limited | Induced pluripotent cell comprising a controllable transgene for conditional immortalization |
GB201902068D0 (en) * | 2019-02-14 | 2019-04-03 | Cambridge Entpr Ltd | Methods of reactivating proliferative capacity non-proliferative tissues |
WO2021015584A1 (ko) * | 2019-07-24 | 2021-01-28 | 주식회사 에스엘바이젠 | 불사화된 줄기세포주의 제조 방법 및 이의 용도 |
CN110622921B (zh) * | 2019-09-29 | 2021-06-15 | 江苏大学 | 阿尔茨海默病病变区FoxG1过表达小鼠模型的构建方法及应用 |
GB202005494D0 (en) * | 2020-04-15 | 2020-05-27 | Reneuron Ltd | Induced pluripotent cell comprising a contollable transgene for conditional immortalisation |
KR20220057859A (ko) | 2020-10-30 | 2022-05-09 | 전상수 | 펜터리 |
US20230407268A1 (en) | 2020-11-06 | 2023-12-21 | Trans Chromosomics, Inc. | Method for producing reversibly immortalized cell |
CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
JPWO2023277153A1 (zh) * | 2021-06-30 | 2023-01-05 | ||
CN113583965A (zh) * | 2021-08-05 | 2021-11-02 | 大连干细胞与精准医学创新研究院 | 一种条件永生化人神经干细胞来源细胞膜纳米囊泡制剂及其制备方法和应用 |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
WO1986003780A1 (en) * | 1984-12-21 | 1986-07-03 | Techniclone Research Partners I | Method for electrically immortalizing lymphoid cells |
DE3531430A1 (de) | 1985-09-03 | 1987-03-05 | Biotest Pharma Gmbh | Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten |
US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US4900322A (en) | 1986-09-22 | 1990-02-13 | Adams James D | Blood component pooling valve and kit |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
NZ241855A (en) | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
AU781922B2 (en) | 1991-12-17 | 2005-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5289858A (en) | 1991-12-18 | 1994-03-01 | Abbott Laboratories | System for accommodating withdrawal of liquid from a bulk supply |
US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
DE656950T1 (de) | 1992-08-21 | 1996-03-14 | Biogen Inc | Tat-derivate transport polypeptide. |
US5580760A (en) | 1993-02-22 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | FUSE binding protein and cDNA therefor |
EP0710283A4 (en) | 1993-07-22 | 1997-07-02 | Merck & Co Inc | THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL |
US5599705A (en) | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
AU683158B2 (en) | 1994-03-03 | 1997-10-30 | Alexion Pharmaceuticals, Inc. | Terminal complement inhibitor fusion genes and proteins |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6713247B1 (en) | 1996-09-03 | 2004-03-30 | Signal Pharmaceuticials, Inc. | Human CNS cell lines and methods of use therefor |
GB2341390B (en) | 1997-05-21 | 2000-11-08 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
EP0893493A3 (de) | 1997-07-21 | 2002-12-04 | Aventis Pharma Deutschland GmbH | Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen |
GB9720585D0 (en) * | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
JP2002505077A (ja) | 1997-12-10 | 2002-02-19 | ワシントン大学 | 抗病原体システムおよびその使用方法 |
US6861257B1 (en) | 1998-04-08 | 2005-03-01 | Shionogi & Co., Ltd. | Methods for isolation of osteoclast precursor cells and inducing their differentiation into osteoclasts |
US6835567B1 (en) | 1998-04-14 | 2004-12-28 | Signal Pharmaceuticals, Inc. | PNS cell lines and methods of use therefor |
US6451558B1 (en) | 1998-08-03 | 2002-09-17 | Novartis Ag | Genes in the control of hematopoiesis |
US6913925B1 (en) | 1998-08-12 | 2005-07-05 | Signal Pharmaceuticals Llc | Human mesencephalon cell lines and methods of use therefor |
AU7497000A (en) | 1999-02-28 | 2000-11-14 | Washington University | Novel transduction molecules and methods for using same |
AU4070500A (en) | 1999-04-05 | 2000-10-23 | Biocrystal Limited | Assay kits and methods for immune complex-mediated activation involving shed antigens |
ATE342275T1 (de) * | 1999-04-12 | 2006-11-15 | Heart Biosystems Gmbh | Vorübergehend-immortalisierte zellen zur verwendung in gentherapie |
US6451601B1 (en) * | 1999-04-12 | 2002-09-17 | Modex Therapeutiques, S.A. | Transiently immortalized cells for use in gene therapy |
US6358739B1 (en) | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US7311920B1 (en) | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
AU1482101A (en) | 1999-11-10 | 2001-06-06 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising renilla gfp |
EP1103615A1 (en) | 1999-11-25 | 2001-05-30 | Universite De Geneve | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
US20010049393A1 (en) | 1999-12-07 | 2001-12-06 | Whitehead Institute For Biomedical Research | Methods for defining MYC target genes and uses thereof |
EP1285577A4 (en) | 2000-05-15 | 2007-05-09 | Sonoko Habu | CHIMERIC MOUSE HAVING IMMUNITY CREATED BY USE OF HUMAN CD34 POSITIVE CELLS AND USE THEREOF |
US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
US20070248618A1 (en) | 2004-03-16 | 2007-10-25 | Cohen David I | Tat-Based vaccine Compositions and Methods of Making and Using Same |
EP1326969B1 (en) | 2000-09-25 | 2009-04-15 | Genetronics, Inc. | Improved system for regulation of transgene expression |
CA2427747A1 (en) | 2000-10-30 | 2002-05-10 | Kalobios, Inc. | Affinity maturation by competitive selection |
US20040241140A1 (en) | 2000-11-01 | 2004-12-02 | Pavlakis George N. | Expression vectors able to elicit improved immune response and methods of using same |
WO2002043477A1 (en) | 2000-12-01 | 2002-06-06 | Central Institute For Experimental Animals | Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse |
WO2002057436A2 (en) | 2001-01-19 | 2002-07-25 | Gendel Limited | Red blood cell from a transgenic animal as vehicle for polypeptide delivery |
US7033744B2 (en) | 2001-03-16 | 2006-04-25 | Naoya Kobayashi | Method for proliferating a liver cell, a liver cell obtained thereby, and use thereof |
EP2060582A1 (en) * | 2001-05-31 | 2009-05-20 | Novartis Ag | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
CN1408850A (zh) * | 2001-09-18 | 2003-04-09 | 王虹 | 人血树突状细胞永生化技术 |
CN100506978C (zh) | 2001-09-21 | 2009-07-01 | 中国人民解放军军事医学科学院野战输血研究所 | 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化 |
GB0124391D0 (en) | 2001-10-11 | 2001-11-28 | Gene Expression Technologies L | Control of gene expression |
US20030147887A1 (en) | 2001-11-02 | 2003-08-07 | Shen-Wu Wang | B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies |
EP1321034A1 (en) * | 2001-12-21 | 2003-06-25 | Pfizer Products Inc. | Disruption of the phosphodieterase 10 gene |
US7670781B2 (en) | 2002-01-03 | 2010-03-02 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
CA2476556A1 (en) | 2002-02-13 | 2003-08-21 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
US7211191B2 (en) | 2004-09-30 | 2007-05-01 | Thermogenesis Corp. | Blood component separation method and apparatus |
WO2003089580A2 (en) | 2002-04-16 | 2003-10-30 | Dana-Farber Cancer Institute, Inc. | Cancer models |
GB2387599B (en) | 2002-04-17 | 2005-08-10 | Jason Peter Brown | Methods for producing antibodies |
WO2003094849A2 (en) | 2002-05-10 | 2003-11-20 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
SI1652857T1 (sl) * | 2002-05-16 | 2009-02-28 | Bavarian Nordic As | Fuzijski protein regulatornih/pomoĹľnih HIV proteinov |
ES2439874T3 (es) * | 2002-05-29 | 2014-01-27 | Regeneron Pharmaceuticals, Inc. | Sistema de expresión en eucariotas inducible |
DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
PT1408114E (pt) | 2002-10-11 | 2007-04-30 | Imvision Gmbh | Moléculas modulares de transportes de antigénios ( moléculas mat ) para modulação de respostas imunitárias, correspondentes construções, processos e utilizações. |
WO2004035535A2 (en) | 2002-10-15 | 2004-04-29 | Yeda Research And Development Co. Ltd. | Erythrocyte differentiation factor, gene encoding same, and methods of use thereof |
EP2048159B1 (en) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | T cell receptor display |
WO2004050885A2 (en) | 2002-12-05 | 2004-06-17 | Imperial College Innovations Limited | Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
US7482016B2 (en) | 2003-03-19 | 2009-01-27 | The J. David Gladstone Institutes | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides |
CA2525519A1 (en) | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
WO2005014785A2 (en) | 2003-06-18 | 2005-02-17 | The George Washington University | Conditionally-immortalized hematopoietic progenitor cell lines |
CA2529752A1 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
IL161903A0 (en) | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
US7705049B2 (en) | 2004-01-21 | 2010-04-27 | New York University | Methods for treating non-melanoma cancers with PABA |
JP2005232148A (ja) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
JP4972549B2 (ja) | 2004-05-19 | 2012-07-11 | イムノコア リミテッド | T細胞レセプターを改善する方法 |
US8143376B2 (en) | 2004-05-19 | 2012-03-27 | Immunocore Limited | High affinity NY-ESO T cell receptor |
ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
WO2006137836A2 (en) | 2004-08-17 | 2006-12-28 | Research Development Foundation | Bacterial vector systems |
GB0420963D0 (en) | 2004-09-21 | 2004-10-20 | Reneuron Ltd | Hepatocyte |
WO2006045064A2 (en) * | 2004-10-20 | 2006-04-27 | Whitehead Institute For Biomedical Research | Cultured hematopoietic stem cells and method for expansion and analysis thereof |
US8795650B2 (en) | 2004-12-09 | 2014-08-05 | The Regents Of The University Of California | Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells |
US20060156422A1 (en) | 2005-01-10 | 2006-07-13 | Medical Research Council | Methods and compositions for the generation of antibodies |
WO2006104978A2 (en) | 2005-03-25 | 2006-10-05 | Curagen Corporation | Antibodies against the tenascin major antigens |
WO2006116512A1 (en) | 2005-04-26 | 2006-11-02 | The Board Of Trustees Of The University Of Illinois, Urbana, Il | Nucleoside compounds and methods of use thereof |
EP1885754B1 (en) | 2005-05-25 | 2011-02-09 | Immunocore Ltd. | T cell receptors which specifically bind to vygfvracl-hla-a24 |
US20090317377A1 (en) | 2005-08-26 | 2009-12-24 | Yeomans David C | Therapy procedure for drug delivery for trigeminal pain |
US20070047583A1 (en) | 2005-08-29 | 2007-03-01 | Siemens Aktiengesellschaft | Method for using a short address in a packet header |
IL286053B2 (en) | 2005-10-18 | 2023-03-01 | Nat Jewish Health | A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin |
CA2626584A1 (en) | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
EP1792627A1 (en) | 2005-12-05 | 2007-06-06 | ImVisioN AG | Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules |
US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
WO2008038002A2 (en) | 2006-09-29 | 2008-04-03 | Medigene Limited | T cell therapies |
EP2134852A4 (en) | 2007-03-13 | 2010-04-28 | Nat Jewish Health | METHODS OF GENERATING ANTIBODIES |
EP2214670A2 (en) | 2007-11-02 | 2010-08-11 | Taiga Biotechnologies, Inc. | Compounds for treating abnormal cellular proliferation |
US9534205B2 (en) | 2008-03-17 | 2017-01-03 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
AU2009246876B2 (en) | 2008-05-16 | 2015-04-02 | Htyr Acquisition Llc | Antibodies and processes for preparing the same |
WO2009149956A2 (en) | 2008-06-13 | 2009-12-17 | Life & Brain Gmbh | Fusion protein and use thereof |
US9169462B2 (en) | 2008-07-21 | 2015-10-27 | Taiga Biotechnologies, Inc. | Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells |
EP3916010A1 (en) | 2008-08-28 | 2021-12-01 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same and methods of identifying agents that modulate myc |
CN107523587A (zh) | 2008-11-06 | 2017-12-29 | 印第安纳大学研究与技术公司 | 增强造血干细胞植入过程的材料和方法 |
WO2010058023A1 (en) | 2008-11-24 | 2010-05-27 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | High affinity t cell receptor and use thereof |
WO2011100477A2 (en) | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
US20120107317A1 (en) | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
RU2018130123A (ru) | 2012-05-03 | 2018-11-07 | Фред Хатчинсон Кансэр Рисёч Сентер | Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии |
DE102012209673A1 (de) | 2012-06-08 | 2013-12-24 | Artcline Gmbh | Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation |
CN114645015A (zh) | 2012-07-20 | 2022-06-21 | 泰加生物工艺学公司 | 造血区室的增强的重建和自动重建 |
WO2014018863A1 (en) | 2012-07-27 | 2014-01-30 | The Board Of Trustees Of The University Of Illinois | Engineering t-cell receptors |
US20140109246A1 (en) | 2012-09-24 | 2014-04-17 | The Regents Of The University Of Colorado, A Body Corporate | Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species |
GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
ES2771251T3 (es) | 2013-03-01 | 2020-07-06 | Us Health | Métodos de producción de poblaciones enriquecidas de células T reactivas con tumores a partir de sangre periférica |
WO2014133567A1 (en) | 2013-03-01 | 2014-09-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
KR20160145186A (ko) | 2014-04-24 | 2016-12-19 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
AU2015371265B2 (en) | 2014-12-24 | 2021-06-03 | Neximmune, Inc | Nanoparticle compositions and methods for immunotherapy |
EP3889176A1 (en) | 2016-01-15 | 2021-10-06 | Berkeley Lights, Inc. | Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
-
2006
- 2006-10-18 IL IL286053A patent/IL286053B2/en unknown
- 2006-10-18 US US11/583,970 patent/US8883507B2/en active Active
- 2006-10-18 IL IL296832A patent/IL296832A/en unknown
- 2006-10-18 CA CA3065947A patent/CA3065947C/en active Active
- 2006-10-18 IN IN6624DEN2014 patent/IN2014DN06624A/en unknown
- 2006-10-18 CA CA2626525A patent/CA2626525C/en active Active
- 2006-10-18 CN CN201510760532.XA patent/CN105483088B/zh active Active
- 2006-10-18 JP JP2008536713A patent/JP2009511081A/ja active Pending
- 2006-10-18 CN CN200680045545.8A patent/CN101330830B/zh active Active
- 2006-10-18 AU AU2006304392A patent/AU2006304392B2/en not_active Ceased
- 2006-10-18 EP EP06826025A patent/EP1942739B1/en active Active
- 2006-10-18 KR KR1020087011791A patent/KR101441693B1/ko active IP Right Grant
- 2006-10-18 KR KR1020137028338A patent/KR101441843B1/ko active IP Right Grant
- 2006-10-18 AT AT06826025T patent/ATE491022T1/de active
- 2006-10-18 DE DE602006018768T patent/DE602006018768D1/de active Active
- 2006-10-18 WO PCT/US2006/040379 patent/WO2007047583A2/en active Application Filing
-
2008
- 2008-04-17 IL IL190946A patent/IL190946A/en active IP Right Grant
-
2009
- 2009-06-22 HK HK09105588.8A patent/HK1126623A1/zh not_active IP Right Cessation
- 2009-06-22 HK HK16110996.5A patent/HK1222890A1/zh unknown
-
2010
- 2010-02-05 US US12/701,383 patent/US9150831B2/en active Active
-
2012
- 2012-10-03 JP JP2012221023A patent/JP5726148B2/ja active Active
-
2013
- 2013-01-30 IL IL224494A patent/IL224494B/en active IP Right Grant
-
2014
- 2014-05-26 JP JP2014108137A patent/JP6302356B2/ja active Active
- 2014-10-08 US US14/509,870 patent/US9796961B2/en active Active
-
2015
- 2015-10-02 US US14/873,296 patent/US20160040129A1/en not_active Abandoned
-
2016
- 2016-02-17 JP JP2016027812A patent/JP2016129515A/ja active Pending
-
2017
- 2017-08-31 JP JP2017166334A patent/JP6655050B2/ja active Active
- 2017-12-24 IL IL256512A patent/IL256512B/en active IP Right Grant
-
2018
- 2018-07-23 US US16/042,904 patent/US10760055B2/en active Active
-
2019
- 2019-01-18 JP JP2019006759A patent/JP6797221B2/ja not_active Expired - Fee Related
- 2019-04-14 IL IL266009A patent/IL266009B/en active IP Right Grant
-
2020
- 2020-06-15 US US16/901,956 patent/US20200308545A1/en not_active Abandoned
- 2020-07-10 JP JP2020119082A patent/JP7078673B2/ja active Active
- 2020-11-02 IL IL278426A patent/IL278426B/en unknown
-
2022
- 2022-01-27 US US17/586,196 patent/US20220145253A1/en not_active Abandoned
- 2022-02-22 JP JP2022025236A patent/JP2022065146A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286053A (en) | A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin | |
GB2428044A (en) | Method of forming mesenchymal stem cells from embryonic stem cells | |
GB2434157A (en) | Platelets from stem cells | |
DE602006017833D1 (de) | Lebervorläuferzellen | |
CY1107014T1 (el) | Χρηση θρεπτικου μεσου κυτταροκαλλιεργειας ελευθερου ορου για την παραγωγη il-18bp σε κυτταρα θηλαστικων | |
WO2005085422A8 (en) | Adult stem cells and uses thereof | |
MX2009004060A (es) | Moduladores de proteina cinasa de triazolpiridazina. | |
ATE426661T1 (de) | Somatische pluripotente zellen | |
GB2441718A (en) | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells | |
MY156588A (en) | Systems using cell culture for production of isoprene | |
RU2012105922A (ru) | Дифференцирование человеческих эмбриональных стволовых клеток | |
UA99700C2 (ru) | Способ приготовления иммортализированной человеческой клеточной линии | |
WO2003065999A3 (en) | Proliferated cell lines and uses thereof | |
MX345399B (es) | Metodo de cultivo de celulas animales. | |
WO2008056368A3 (en) | Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases | |
SG152229A1 (en) | Stem cell fusion model of carcinogenesis | |
GB2453074A (en) | Differentiation of primate pluripotent cells to hepatocyte-lineage cells | |
WO2013184193A3 (en) | Cancer stem cells and methods of using the same | |
BR112019001783A2 (pt) | mamífero não humano, e, métodos para produzir o mamífero não humano e de triagem de um composto. | |
EP1687413B8 (en) | Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease | |
GB2464075A (en) | Parthenote-derived stem cells and methods of making and using them | |
IN2012DN06432A (zh) | ||
MX2012001004A (es) | Proceso para la obtencion de miofibroblastos. | |
EP1676911A4 (en) | NEW RECOMBINANT ANIMAL CELLS WITH HIGH PROTEIN PRODUCTION, CORRESPONDING FIXING METHOD AND METHOD FOR PREPARING MASS PROTEINS USING THE SAME | |
WO2008070258A3 (en) | Directed differentiation of human embryonic stem cells into mesenchymal/stromal cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20231014 |